melpo with western squareLignaMed, LLC is a drug development company with a fast track strategy to market approval and an early exit. The company’s initial product, LGM-2605, will be utilized to reduce side effects and increase effectiveness of radiation treatment of chest cancers as well as for protection against radiological threats. The preclinical development of LGM-2605 has been generously supported by the Radiation Nuclear Countermeasure Program (RNCP), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

LignaMed, LLC was founded by a key opinion leader in lung damage and inflammation and was spun out from the University of Pennsylvania through the UPstart Company Incubator.